SCHEMBL4933201

SCHEMBL4933201

Clc1ccc2c(c1)nc(SCc1ccccc1Cl)n2-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CASP3 P42574 1/20 0.50
HTT P42858 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
PTGDR2 Q9Y5Y4 2/20 0.49
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
LMNA P02545 1/20 0.46
METAP2 P50579 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933130 0.86 PDE7A (0.55) MAPTNPC1RAB9ASMN1; SMN2PTGDR2
SCHEMBL4929819 0.79 RAB9A (0.51) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4932809 0.76 TBXA2R (0.56) NPC1RAB9ASMN1; SMN2PTGDR2LMNA
SCHEMBL4928460 0.74 SMN1; SMN2 (0.49) MAPTKMT2ASMN1; SMN2TDP1L3MBTL1
SCHEMBL4928268 0.73 LMNA (0.48) SMN1; SMN2PTGDR2LMNA
SCHEMBL4921552 0.71 KMT2A (0.52) MAPTKMT2ASMN1; SMN2L3MBTL1HTT
SCHEMBL20776029 0.70 FGFR1 (0.50) MAPTMEN1KMT2ASMN1; SMN2TDP1
SCHEMBL541394 0.70 ALDH1A1 (0.68) MAPTNPC1MEN1KMT2ASMN1; SMN2
SCHEMBL646265 0.70 FGFR1 (0.50) MAPTNPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL4921902 0.70 KMT2A (0.51) MAPTKMT2ASMN1; SMN2L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US claimed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP claimed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MAPT 4574/4885NPC1 1300/4885RAB9A 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.